Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04193176 · ClinicalTrials.gov registry record · Phase 3
Efficacy and Safety of Gefapixant (MK-7264) in Women With Chronic Cough and Stress Urinary Incontinence (MK-7264-042)
A Phase 3 study of Chronic Cough, sponsored by Merck Sharp & Dohme.
- Completed
- Registry status
- Phase 3
- Development phase
- 376
- Enrollment target
- 20
- Study locations
NCT04193176 is a Phase 3 study of Chronic Cough that has completed, run by Merck Sharp & Dohme. The registered enrollment target is 376 participants. The trial reports 20 study locations across 14 states.
The verdict
NCT04193176, a Phase 3 study of Chronic Cough, has completed, sponsored by Merck Sharp & Dohme.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 376 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to evaluate the efficacy and safety of gefapixant, in improving symptoms of cough-induced stress urinary incontinence (SUI) in adult female participants with refractory or unexplained chronic cough. The primary hypothesis is that gefapixant is superior to placebo in reducing the frequency of cough-induced SUI episodes over 12 weeks.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Gefapixant
Study Locations (20)
Florida
- Health Awareness, Inc. ( Site 0038) - Jupiter
- Well Pharma Medical Research, Corp. ( Site 0040) - Miami
- Lenus Research & Medical Group Llc ( Site 0007) - Sweetwater
- Florida Pulmonary Research Institute, LLC ( Site 0008) - Winter Park
North Carolina
- American Health Research ( Site 0027) - Charlotte
- Clinical Research of Gastonia ( Site 0016) - Gastonia
- PMG Research of Wilmington ( Site 0004) - Wilmington
Virginia
- TPMG Clinical Research ( Site 0025) - Newport News
- Tidewater Physician Multispecialty Group, PC ( Site 0028) - Williamsburg
California
- Center for Clinical Trials, LLC ( Site 0021) - Paramount
Maine
- Paul A. Shapero, MD ( Site 0037) - Bangor
Maryland
- Chesapeake Clinical Research, Inc ( Site 0022) - White Marsh
Missouri
- University of Missouri ENT & Allergy Center ( Site 0010) - Columbia
Nevada
- Alliance for Multispecialty Research, LLC ( Site 0035) - Las Vegas
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 376 participants |
| Start Date | 2020-05-10 |
| Est. Completion | 2022-09-02 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04193176
The ClinicalTrials.gov registry entry for NCT04193176 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 376 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Merck Sharp & Dohme, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Chronic Cough appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT04193176 reports 20 study locations spanning 14 distinct geographic areas - top geographies include Florida, North Carolina, Virginia.
Frequently Asked Questions
What is clinical trial NCT04193176 about?
NCT04193176 is a clinical study titled "Efficacy and Safety of Gefapixant (MK-7264) in Women With Chronic Cough and Stress Urinary Incontinence (MK-7264-042)". The purpose of this study is to evaluate the efficacy and safety of gefapixant, in improving symptoms of cough-induced stress urinary incontinence (SUI) in adult female participants with refractory or unexplained chronic cough. The primary hypothesis is that gefapixant is superior to placebo in redu...
What is the current status of trial NCT04193176?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 376 participants. The study started on 2020-05-10. Estimated completion is 2022-09-02.
What conditions does trial NCT04193176 study?
This clinical trial studies the following conditions: Chronic Cough.
What interventions are being tested in trial NCT04193176?
The interventions under investigation include: Placebo (DRUG), Gefapixant (DRUG).
Who is sponsoring clinical trial NCT04193176?
This trial is sponsored by Merck Sharp & Dohme, which has 558 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04193176 being conducted?
This trial has 20 study locations across California, Florida, Maine, Maryland, Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Chronic Cough
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.